Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Hinge Health (HNGE) Gains from Investment Securities (2024 - 2025)

Hinge Health (HNGE) has disclosed Gains from Investment Securities for 2 consecutive years, with $870000.0 as the latest value for Q4 2025.

Quarterly Gains from Investment Securities rose 5700.0% to $870000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Jun 2025, changed N/A year-over-year, with the annual reading at $1.6 million for FY2025, 46.44% down from the prior year.
Gains from Investment Securities hit $870000.0 in Q4 2025 for Hinge Health, down from $8.5 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $8.5 million in Q2 2025 to a low of -$18000.0 in Q3 2024.